ASCO 2023 | App-based intervention for breast cancer adherence & outcomes

Ilana Graetz, PhD, Emory University, Atlanta, GA, shares the results of the randomized THRIVE Breast Cancer App study (NCT03592771) aimed to evaluate the effectiveness of an app integrated with patient-reported outcomes and electronic health records, along with tailored messages, to improve adherence to adjuvant endocrine therapy (AET) among women with hormone receptor-positive breast cancer. Participants were randomized into three groups: App, App+Feedback (AF), and Usual Care (UC). While the intervention did not significantly improve AET adherence, the AF group reported better mental health during the intervention period. Additionally, the AF group had fewer higher-cost care encounters at 12 months compared to the UC group. The findings suggest that symptom monitoring apps with tailored messages could be scalable and effective in improving outcomes for breast cancer patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.